A Polish biotech spin-off developing personalized cancer vaccines has secured PLN 10.5 million (approximately $2.86 million at November 2025 exchange rates) in a seed round that attracted backing from a newly formed consortium of deep-tech investors.
VAXICAN announced the funding closed in November 2025, marking the inaugural deal for the DeepTech Capital Consortium. The group brings together established funds Rubicon Partners, iif.vc, and Radix Ventures, along with individual investors from the Rynkowy Rebeliant community. Demand exceeded expectations. Rubicon Partners, representing the consortium, said the round was oversubscribed.
A signing ceremony took place November 13, 2025, at the University of Gdańsk, where the company traces its academic roots.
Building Vaccines From Viral Shells
The startup's approach centers on enveloped virus-like particles, known in the field as eVLPs, constructed from a paramyxovirus scaffold. These engineered particles mimic the structure of viruses without carrying infectious genetic material, a design intended to trigger robust immune responses against cancer targets.
The company also runs its own genomic sequencing operation through a division called Vaxican Genomics, which holds certification from Oxford Nanopore Technologies as a service provider. That in-house sequencing capability, built around next-generation sequencing technology, gives the team direct control over data pipelines that feed their computational models.
Two vaccine candidates are moving toward clinical readiness, according to the company's exhibitor listing at the BIO 2026 conference. One targets HER2-positive breast cancer. The other aims at neuroblastoma, a pediatric cancer that arises in nerve tissue.
From COVID Sequencing to Cancer Immunotherapy
Founder and CEO Łukasz Rąbalski made his name during the early pandemic. The virologist and assistant professor at the University of Gdańsk's Intercollegiate Faculty of Biotechnology led the team that sequenced the first complete SARS-CoV-2 genome from a Polish patient in 2020. That work put the Gdańsk lab on the map for infectious disease surveillance.
Co-founder Krzysztof Łepek, who serves as chief operating officer, also worked on Poland's early coronavirus sequencing efforts. Both brought their virology backgrounds to bear on a different problem: training the immune system to recognize and attack cancer cells.
The company registered as a spin-off from the University of Gdańsk and Medical University of Gdańsk in September 2019, before the pandemic shifted much of the team's attention to SARS-CoV-2. With the seed round, VAXICAN added Matt Sagan to the management board as chief growth officer and chief financial officer.
Milestones and Manufacturing Scale-Up
The funding will accelerate preclinical programs, expand laboratory infrastructure, grow the research team, and scale the genomics services division, according to university announcements and Polish startup media coverage.
Months after the initial closing, the company reported hitting three technical milestones that unlocked a second tranche of capital, pushing total secured funding above PLN 9 million. Those achievements included construction of a 230-square-meter semi-industrial lab, development of a proprietary purification method for the eVLP particles, and production output for the HER2-targeted vaccine that came in nearly five times above minimum targets.
The team also secured a PLN 6.3 million grant from European Union programs for arbovirus diagnostics work, with an additional PLN 4.5 million in co-funding, Polish business press reported.
Riding a Wave of Vaccine Optimism
VAXICAN's fundraise came as the broader cancer vaccine sector gained momentum, both in investor interest and clinical validation. Market projections cited by the University of Gdańsk showed the cancer vaccine industry growing from over $11 billion in 2025 to approximately $29 billion by 2034, though such forecasts often assume smooth regulatory paths that don't always materialize.
Moderna and Merck provided a jolt of confidence in August 2026 when they released Phase 3 data showing their personalized melanoma vaccine, combined with Keytruda, reduced the risk of recurrence or death. Moderna's stock jumped on the news. Around the same time, Evaxion, a Danish competitor also using artificial intelligence for vaccine design, announced expansions to its development pipeline.
Whether that enthusiasm will carry through regulatory hurdles and commercial launch remains an open question. Cancer vaccines have stumbled before, despite promising early data.
"With investor support and the synergy of scientific, technological and business competencies, VAXiCAN will accelerate development of the first two therapeutic cancer vaccine candidates, steering them toward clinical readiness," Rąbalski said in the company's announcement.
The path from preclinical promise to approved medicine is long. VAXICAN is betting its combination of viral engineering, machine learning, and in-house genomics will shorten that timeline.
